



bioRxiv is receiving many new papers on coronavirus SARS-CoV-2. A reminder: these are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information.

New Results

4 comments

Previous

Next

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple endemic, epidemic and bat coronavirus

Timothy P. Sheahan, Amy C. Sims, Shuntai Zhou, Rachel L. Graham, Collin S. Hill, Sarah R. Leist, Alexandra Schäfer, Kenneth H. Dinnon III, Stephanie A. Montgomery, Maria L. Agostini, Andrea J. Pruijssers, James D. Chapell, Ariane J. Brown, Gregory R. Bluemling, Michael G. Natchus, Manohar Saindane, Alexander A. Kolykhalov, George Painter, Jennifer Harcourt, Azaibi Tamin, Natalie J. Thornburg, Ronald Swanstrom, Mark R. Denison, Ralph S. Baric

doi: <https://doi.org/10.1101/2020.03.19.997890>

This article is a preprint and has not been certified by peer review [what does this mean?].

Posted March 20, 2020.

Download PDF

Email

Share

Citation Tools

Tweet

Like 1.1K

COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

Subject Area

Microbiology

Subject Areas

All Articles

Animal Behavior and Cognition

Biochemistry

Bioengineering

Bioinformatics

Biophysics

Cancer Biology

Cell Biology

Clinical Trials*

Developmental Biology

Ecology

Epidemiology*

Evolutionary Biology

Genetics

Genomics

Immunology

Microbiology

Molecular Biology

Neuroscience

Paleontology

Pathology

Pharmacology and Toxicology

Physiology

Abstract

Full Text

Info/History

Metrics

Preview PDF

Abstract

Coronaviruses (CoVs) traffic frequently between species resulting in novel disease outbreaks, most recently exemplified by the newly emerged SARS-CoV-2. Herein, we show that the ribonucleoside analog β -D-N⁴-hydroxycytidine (NHC, EIDD-1931) has broad spectrum antiviral activity against SARS-CoV 2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c Bat-CoVs, as well as increased potency against a coronavirus bearing resistance mutations to another nucleoside analog inhibitor. In mice infected with SARS-CoV or MERS-CoV, both prophylactic and therapeutic administration of EIDD-2801, an orally bioavailable NHC-prodrug (b-D-N⁴-hydroxycytidine-5'-isopropyl ester), improved pulmonary function, and reduced virus titer and body weight loss. Decreased MERS-CoV yields *in vitro* and *in vivo* were associated with increased transition mutation frequency in viral but not host cell RNA, supporting a mechanism of lethal mutagenesis. The potency of NHC/EIDD-2801 against multiple coronaviruses, its therapeutic efficacy, and oral bioavailability *in vivo*, all highlight its potential utility as an effective antiviral against SARS-CoV-2 and other future zoonotic coronaviruses.

Copyright The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Blog posts linking to this article:

Lab Land, 06 Apr 2020

towards data science, 02 Apr 2020

Science Media Centre of Canada » Languages » English, 23 Mar 2020

Science Media Centre of Canada » Languages » English, 23 Mar 2020

Tweets referencing this article:

tamzamanlıdeli

@tamzamanlıdeli

Bu beni en çok heyecanlandıran ilaç <https://t.co/eyzj40uSzM>

06:56AM

Bal'O

@kbal_o

@oskk9 | <https://t.co/LrS2nfRZss>

06:47AM

RA☀️HORUS

@1915mart

RT @unsuzdam : Coronavirüslere karşı etkinliği kanıtlanan ilk antiviral ilaç ABD'nin North

Plant Biology

Scientific Communication and Education

Synthetic Biology

Systems Biology

Zoology

* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).

Proudly supported by  CHAN ZUCKERBERG INITIATIVE

4 Comments BioRxiv  Disqus' Privacy Policy Login ▾ Recommend 3 Tweet Share

Sort by Newest ▾



Join the discussion...

LOG IN WITH

OR SIGN UP WITH DISQUS 

Name

**Sinai Immunol Review Project** • 10 days ago

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple 2 endemic, epidemic and bat coronavirus

Sheahan et al. 2020

Main Findings: β -D-N4 30 -hydroxycytidine (NHC, EIDD-1931) is an orally bioavailable ribonucleoside with antiviral activity against various RNA viruses including Ebola, Influenza and CoV. NHC activity introduced mutations in the viral (but not cellular) RNA in a dose dependent manner that directly correlated with a decrease in viral titers. Authors show that NHC inhibited multiple genetically distinct Bat-CoV viruses in human primary epithelial cells without affecting cell viability even at high concentrations (100 μ M). Prophylactic oral administration of NHC in C57BL/6 mice reduce lung titers of SARS-CoV and prevented weight loss and hemorrhage. Therapeutic administration of NHC in C57BL/6 mice 12 hours post infected with SARS-CoV reduced acute lung injury, viral titer, and lung hemorrhage. The degree of clinical benefit was dependent on the time of treatment initiation post infection. The authors also demonstrate that NHC reduces MERS-CoV infection titers, pathogenesis, and viral RNA in prophylactic and therapeutic settings.

Caveats: Most of the experiments were conducted using MERS-CoV and SARS-CoV and...
see more

^ | ▾ • Reply • Share ▾

**Jeremy Green** • 19 days ago

Could the authors add illustrations of the chemical structures of the EIDD compounds? These are, after all, the subject of the paper.

^ | ▾ • Reply • Share ▾

**Grant Jacobs** • a month ago

Could the authors add 'in mice' in the abstract, please? Better still, in the title.

1 ^ | ▾ • Reply • Share ▾

**Max Sargeson** → **Grant Jacobs** • a month ago

"In mice"

Since the ribonucleoside analogue targets the RNA-virus as it replicates, not the mouse, it's probable that it works in humans; moreover the cross-species pharmacokinetics of things like nucleosides are generally comparable between mammals.

1 ^ | ▾ 1 • Reply • Share ▾

 Subscribe  Add Disqus to your site  Add Disqus  Do Not Sell My Data

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

Continue

Find out more